Last year, Quest Diagnostics Inc generated 5.96B USD for its biggest-performing segment, Routine clinical testing services. The United States made the largest contribution, accounting for 11.04B USD last year. For the latest quarter, Quest Diagnostics Inc reported the revenue of 1.24B USD for the period ending 2023-12-31, which came from the top-performing segment, Routine clinical testing services. United States contributed the highest revenue, at 2.90B USD.

By Business

Revenue

Proportion

Annual

Annual

Quarterly

Routine clinical testing services

Gene-based and esoteric testing services

Anatomic pathology testing services

All other

COVID-19 testing services

All other

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

Routine clinical testing services

5.96B(54.00%)

5.03B(51.00%)

4.72B(51.00%)

4.35B(44.00%)

4.29B(39.79%)

3.84B(40.65%)

4.21B(54.44%)

4.22B(56.00%)

Gene-based and esoteric testing services

4.19B(38.00%)

3.85B(39.00%)

3.52B(38.00%)

3.16B(32.00%)

2.88B(26.68%)

2.10B(22.23%)

2.62B(33.91%)

2.41B(31.99%)

Anatomic pathology testing services

662.10M(6.00%)

592.32M(6.00%)

555.12M(6.00%)

592.98M(6.00%)

553.00M(5.13%)

482.00M(5.11%)

579.00M(7.49%)

578.00M(7.67%)

All other

220.70M(2.00%)

--(--)

COVID-19 testing services

--(--)

98.72M(1.00%)

185.04M(2.00%)

1.48B(15.00%)

2.77B(25.68%)

2.72B(28.85%)

--(--)

All other

--(--)

296.16M(3.00%)

277.56M(3.00%)

296.49M(3.00%)

294.00M(2.73%)

298.00M(3.16%)

321.00M(4.15%)

327.00M(4.34%)

By Region

Revenue

Proportion

Annual

Annual

Quarterly

United States

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

United States

11.04B(100.00%)

9.87B(100.00%)

9.25B(100.00%)

9.88B(100.00%)

10.79B(100.00%)

9.44B(100.00%)

7.73B(100.00%)